Medical Device Epidemiology Network: Developing Partnership Between the Center for Devices and Radiological Health and Academia; Public Workshop, 14170-14171 [2010-6446]
Download as PDF
srobinson on DSKHWCL6B1PROD with NOTICES
14170
Federal Register / Vol. 75, No. 56 / Wednesday, March 24, 2010 / Notices
reflected light from diffusely
backscattered light, coming from deeper
tissue layers. In combination with
suggested data processing algorithm,
based on correlation analysis, this
allows one to enhance imaging of the
hidden subsurface tissue structure
(texture).
Applications:
• The polarization adaptor of the
invention can enhance the quality of
imaging and diagnostics of conventional
colposcope and thus improve early
detection of pathologies, especially the
status of the collagen network beneath
the surface of the cervix.
• Screening and diagnostics of
cervical abnormalities which can lead to
cancer or pre-term delivery.
Advantages:
• Improved characterization of
cervical tissue for better diagnosis of
abnormalities in cervical, vaginal, and
vulva tissues. Minimally invasive
measurement and analysis of diffusely
backscattered light using specific image
processing procedures as provided in
the invention, may contribute useful
information about internal structures of
biological tissues in more detail as
compared with existing methods.
• The device can improve early
detection of cervical cancer and thus
save lives. Recent large-scale National
Cancer Institute-sponsored clinical trial
demonstrated that colposcopy failed to
detect 33% of high-grade precancerous
lesions in women referred with
questionable Pap results. An
improvement in detection capabilities is
thus very much needed (https://
biomedreports.com/articles/mostpopular/12449-non-invasive-device-forcervical-cancer).
• Enhanced diagnostics may result in
the reduction of repeat examinations
usually used for a definitive diagnostics
for cervical cancer. Thus it may have
favorable impact on healthcare costs.
• Can be readily adapted to any
conventional colposcope.
Development Status:
• A working prototype was built.
• Need to gather clinical data and
demonstrate clinical utility.
Market:
• Colposcopy is now routinely used
for diagnostics of cervical cancer and
other tissue abnormalities in female
organs.
• In the U.S. alone, over $6 billion is
spent annually on the screening,
diagnosis and treatment of women with
cervical cancer. Diagnosing cervical
cancer is often a long and uncertain
process requiring repeat visits to the
Doctor’s office. Approximately three (3)
million colposcopy procedures are
performed annually, with many repeat
VerDate Nov<24>2008
16:24 Mar 23, 2010
Jkt 220001
exams aimed at a definitive diagnosis.
The U.S. colposcopy market alone is
approximately $1 billion annually
(https://biomedreports.com/articles/
most-popular/12449-non-invasivedevice-for-cervical-cancer).
• The repeat examinations typically
required to arrive at a definitive
determination are both stressful and
expensive. For women with
precancerous lesions, the long
diagnostic cycle can allow the disease to
progress and develop into invasive, lifethreatening cancers. By providing a
more definitive test, the device offered
in this invention will allow clinicians to
more effectively manage and treat
millions of women who are at risk of
cervical cancer.
In light of the above it is evident that
a device that can be adapted to
conventional instruments and provide
for improved diagnostics will also be
commercially rewarding.
Inventors: Amir H. Gandjbakhche et
al. (NICHD).
Related Publications:
1. Jacques SL, Roman JR, Lee K.
Imaging superficial tissues with
polarized light. Lasers Surg Med.
2000;26(2):119–129. [PubMed:
10685085].
2. Jacques SL, Ramella-Roman JC, Lee
K. Imaging skin pathology with
polarized light. J Biomed Opt. 2002 Jul
7;7(3):329–340. [PubMed: 12175282].
3. Ramella-Roman JC, Lee K, Prahl
SA, Jacques SL. Design, testing, and
clinical studies of a handheld polarized
light camera. J Biomed Opt. 2004 Nov–
Dec;9(6):1305–1310. [PubMed:
15568952].
4. Sviridov AP, Ulissi Z,
Chernomordik V, Hassan M, Boccara
AC, Gandjbakhche A, ‘‘Analysis of
Biological Tissue Textures Using
Measurements of Backscattered
Polarized Light’’; OSA Topical Meeting
on Biomedical Optics, c.WD8 (2006).
5. Sviridov AP, Ulissi Z,
Chernomordik V, Hassan M,
Gandjbakhche A. Visualization of
biological texture using correlation
coefficient images. J Biomed Opt. 2006
Nov–Dec;11(6):060504. [PubMed:
17212522].
6. Sviridov AP, Chernomordik V,
Hassan M, Boccara AC, Russo A, Smith
P, Gandjbakhche A. Enhancement of
hidden structures of early skin fibrosis
using polarization degree patterns and
Pearson correlation analysis. J Biomed
Opt. 2005 Sep–Oct;10(5):051706.
[PubMed: 16292958].
Patent Status: U.S. Provisional
Application No. 61/242,652 filed 15 Sep
2009, entitled ‘‘Polarization Adapter for
Colposcope’’ (HHS Reference No. E–
161–2009–0–US–01).
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Licensing Status: Available for
licensing.
Licensing Contacts: Uri Reichman,
Ph.D., MBA; 301–435–4616;
UR7a@nih.gov; or Michael Shmilovich,
J.D.; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The Eunice Shriver National Institute of
Child Health and Human Development,
Section on Analytical and Functional
Biophotonics, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the polarization camera
for cervical tissue characterization.
Please contact Joseph Conrad, Ph.D. at
301–435–3107 or
jmconrad@mail.nih.gov for more
information.
Dated: March 16, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–6433 Filed 3–23–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Medical Device Epidemiology Network:
Developing Partnership Between the
Center for Devices and Radiological
Health and Academia; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing a public workshop
entitled ‘‘Medical Device Epidemiology
Network (MDEpiNet): Developing
Partnership Between the Center for
Devices and Radiological Health and
Academia.’’ The purpose of the public
workshop is to facilitate discussion
among FDA and academic researchers
with expertise in epidemiology and
health services research on issues
related to the methodology for studying
medical device performance.
Date and Time: The public workshop
will be held on April 30, 2010, from 8
a.m. to 5 p.m. Participants are
encouraged to arrive early to ensure
time for parking and security screening
before the meeting. Security screening
will begin at 7 a.m., and registration will
begin at 7:30 a.m.
Location: The public workshop will
be held at the FDA White Oak Campus,
E:\FR\FM\24MRN1.SGM
24MRN1
Federal Register / Vol. 75, No. 56 / Wednesday, March 24, 2010 / Notices
10903 New Hampshire Ave., Silver
Spring, MD 20993.
Contact: Kristen Van Dole, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993, 301–796–6334, email:
Kristen.VanDole@fda.hhs.gov; or Mary
Beth Ritchey, Center for Devices and
Radiological Health (CDRH), Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993, 307–796–6638, email:
MaryElizabeth.Ritchey@fda.hhs.gov.
Registration: Email your name, title,
organization affiliation, address, and
email contact information to Kristen
Van Dole (see Contact) by April 19,
2010. There is no fee to attend the
public workshop, but attendees must
register in advance. Registration will be
on a first-come, first-served basis and
we ask that one person per institution
be selected to represent the entity at the
workshop. Non-U.S. citizens are subject
to additional security screening, and
they should register as soon as possible.
If you need special accommodations
because of a disability, please contact
Mary Beth Ritchey (see Contact) at least
7 days before the public workshop.
SUPPLEMENTARY INFORMATION:
srobinson on DSKHWCL6B1PROD with NOTICES
I. Why Are We Holding This Public
Workshop?
The purpose of the public workshop
is to facilitate discussion among FDA
and the academic epidemiology and
health services research community on
issues related to the methodology of
studies for medical device performance.
We aim to reach out to academic
centers that have epidemiologic,
statistical, and clinically relevant
expertise to establish a network that will
work with FDA experts to determine the
evidence gaps and questions, datasets
and approaches for conducting robust
analytic studies and improve our
understanding of the performance of
medical devices (including comparative
effectiveness studies). The centers
participating in the network will be
expected to take part in other FDAhosted scientific workshops that address
methods for medical device comparative
analyses, best practices and best design
and analysis methods.
II. Who is the Target Audience for This
Public Workshop? Who Should Attend
This Public Workshop?
This workshop is open to all
interested parties. The target audience is
comprised of academic researchers with
experience in epidemiology or health
services research with an interest in
medical device outcome and
epidemiologic study methodology.
VerDate Nov<24>2008
16:24 Mar 23, 2010
Jkt 220001
III. What Are the Topics We Intend to
Address at the Public Workshop?
We intend to discuss a large number
of issues at the workshop, including, but
not limited to:
• Gaps and challenges in medical
device outcomes and epidemiologic
studies;
• Creation of the Medical Device
Epidemiology Network (MdEpiNet)
infrastructure; and
• Opportunities for medical device
epidemiologic research and
partnerships between CDRH and
Academia.
IV. Where Can I Find Out More About
This Public Workshop?
14171
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5208,
MSC 7852, Bethesda, MD 20892, (301) 435–
1165, walkermc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 16, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–6435 Filed 3–23–10; 8:45 am]
Background information on the public
workshop, registration information, the
agenda, information about lodging, and
other relevant information will be
posted, as it becomes available, on the
Internet at https://www.fda.gov/cdrh/
meetings.html.
BILLING CODE 4140–01–P
Dated: March 18, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Center for Scientific Review; Notice of
Closed Meetings
[FR Doc. 2010–6446 Filed 3–23–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: AMCB and ADDT.
Date: March 31, 2010.
Time: 11 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Mary Clare Walker, PhD,
Scientific Review Officer, Center for
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Reproductive Biology.
Date: April 6–7, 2010.
Time: 9 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting)
Contact Person: Robert Garofalo, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6156,
MSC 7892, Bethesda, MD 20892, 301–435–
1043, garofalors@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Brain Disorders.
Date: April 15–16, 2010.
Time: 10 a.m. to 5 p.m.
E:\FR\FM\24MRN1.SGM
24MRN1
Agencies
[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Pages 14170-14171]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6446]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Medical Device Epidemiology Network: Developing Partnership
Between the Center for Devices and Radiological Health and Academia;
Public Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing a public
workshop entitled ``Medical Device Epidemiology Network (MDEpiNet):
Developing Partnership Between the Center for Devices and Radiological
Health and Academia.'' The purpose of the public workshop is to
facilitate discussion among FDA and academic researchers with expertise
in epidemiology and health services research on issues related to the
methodology for studying medical device performance.
Date and Time: The public workshop will be held on April 30, 2010,
from 8 a.m. to 5 p.m. Participants are encouraged to arrive early to
ensure time for parking and security screening before the meeting.
Security screening will begin at 7 a.m., and registration will begin at
7:30 a.m.
Location: The public workshop will be held at the FDA White Oak
Campus,
[[Page 14171]]
10903 New Hampshire Ave., Silver Spring, MD 20993.
Contact: Kristen Van Dole, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave., Silver
Spring, MD 20993, 301-796-6334, email: Kristen.VanDole@fda.hhs.gov; or
Mary Beth Ritchey, Center for Devices and Radiological Health (CDRH),
Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring,
MD 20993, 307-796-6638, email: MaryElizabeth.Ritchey@fda.hhs.gov.
Registration: Email your name, title, organization affiliation,
address, and email contact information to Kristen Van Dole (see
Contact) by April 19, 2010. There is no fee to attend the public
workshop, but attendees must register in advance. Registration will be
on a first-come, first-served basis and we ask that one person per
institution be selected to represent the entity at the workshop. Non-
U.S. citizens are subject to additional security screening, and they
should register as soon as possible. If you need special accommodations
because of a disability, please contact Mary Beth Ritchey (see Contact)
at least 7 days before the public workshop.
SUPPLEMENTARY INFORMATION:
I. Why Are We Holding This Public Workshop?
The purpose of the public workshop is to facilitate discussion
among FDA and the academic epidemiology and health services research
community on issues related to the methodology of studies for medical
device performance.
We aim to reach out to academic centers that have epidemiologic,
statistical, and clinically relevant expertise to establish a network
that will work with FDA experts to determine the evidence gaps and
questions, datasets and approaches for conducting robust analytic
studies and improve our understanding of the performance of medical
devices (including comparative effectiveness studies). The centers
participating in the network will be expected to take part in other
FDA-hosted scientific workshops that address methods for medical device
comparative analyses, best practices and best design and analysis
methods.
II. Who is the Target Audience for This Public Workshop? Who Should
Attend This Public Workshop?
This workshop is open to all interested parties. The target
audience is comprised of academic researchers with experience in
epidemiology or health services research with an interest in medical
device outcome and epidemiologic study methodology.
III. What Are the Topics We Intend to Address at the Public Workshop?
We intend to discuss a large number of issues at the workshop,
including, but not limited to:
Gaps and challenges in medical device outcomes and
epidemiologic studies;
Creation of the Medical Device Epidemiology Network
(MdEpiNet) infrastructure; and
Opportunities for medical device epidemiologic research
and partnerships between CDRH and Academia.
IV. Where Can I Find Out More About This Public Workshop?
Background information on the public workshop, registration
information, the agenda, information about lodging, and other relevant
information will be posted, as it becomes available, on the Internet at
https://www.fda.gov/cdrh/meetings.html.
Dated: March 18, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-6446 Filed 3-23-10; 8:45 am]
BILLING CODE 4160-01-S